[{"indications": "Indications\u00a0treatment of acute migraine", "name": "FROVATRIPTAN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.7 Analgesics", "4.7.4 Antimigraine drugs", "4.7.4.1 Treatment of acute migraine", "5HT1-receptor agonists", "FROVATRIPTAN"], "cautions": "Cautions\u00a0see under 5HT1-receptor agonists above; interactions: Appendix 1 (5HT1 agonists)", "side-effects": "Side-effects\u00a0see under 5HT1-receptor\r\nagonists above; also dry mouth, dyspepsia, abdominal pain,\r\nparaesthesia, drowsiness, headache, visual disturbances, sweating; less commonly diarrhoea, dysphagia, flatulence, tachycardia,\r\npalpitation, hypertension, rhinitis, pharyngitis, sinusitis, laryngitis,\r\ntremor, anxiety, asthenia, insomnia, confusion, nervousness, impaired\r\nconcentration, agitation, depression, depersonalisation, taste disturbances,\r\nmicturition disorders, thirst, dehydration, arthralgia, muscle stiffness,\r\ntinnitus, vertigo, pruritus; rarely constipation,\r\ngastro-oesophageal reflux, irritable bowel syndrome, hiccup, peptic\r\nulcer, stomatitis, bradycardia, hyperventilation, amnesia, abnormal\r\ndreams, hypertonia, hypotonia, breast tenderness, hypocalcaemia, hypoglycaemia,\r\nbilirubinaemia, epistaxis, urticaria, pyrexia, and purpura", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/128095.htm", "doses": ["2.5\u00a0mg as soon as possible after onset repeated after\r\n2 hours if migraine recurs (patient not responding should not take\r\nsecond dose for same attack); max. 5\u00a0mg in 24 hours; child and adolescent under 18 years not recommended"], "pregnancy": "Pregnancy\u00a0\n(From 5HT1-receptor agonists: British National Formulary)\nPregnancy\u00a0There is limited experience of using 5HT1-receptor agonists during pregnancy; manufacturers advise that they should be avoided unless the potential benefit outweighs the risk."}]